GlassScriptPhysician profile
Alexis Jo Brown
NPI 1245670934
$1,333.47
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $190 · 2021: $41.35 · 2022: $325 · 2023: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $261.06 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $199.60 | 2021-2023 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $137.51 | 2019-2023 | Farxiga |
| Medtronic Vascular, INC. | $118.50 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.97 | 2022-2023 | |
| Astellas Pharma US INC | $83.61 | 2019-2023 | Veozah |
| Lilly USA, LLC | $75.09 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $71.42 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $64.95 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $62.77 | 2019-2020 | |
| Amgen INC. | $50.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.57 | 2019-2022 | |
| Abbott Laboratories | $24.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.61 | 2023 | |
| Antares Pharma, INC. | $15.04 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13.07 | 2023 | Quviviq |
| Shire North American Group INC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.